Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
Terminated
Oncology Specialties, Alabama
Phase 2
2004-02-01
In this phase II study besides evaluating for safety, the primary efficacy parameter is to
evaluate the incidence of patients who have had a response to Trisenox by evidence of
increased blood counts (red, white, or platelets) and/or by decrease or transfusion
dependency. The secondary efficacy parameter is the assessment of the tolerability of the new
dosing schedule.
Arsenic trioxide will be administered intravenously over 1 to 2 hours with a loading dose of
0.30mg/kg for days 1-5 of the first week and then twice weekly for 27 weeks for a total of 28
weeks.
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Completed
National Cancer Institute (NCI)
Phase 1
1998-04-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients
who have advanced hematologic cancer.
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Completed
Memorial Sloan Kettering Cancer Center
Phase 1
1998-04-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients
who have advanced hematologic cancer.
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
Completed
National Cancer Institute (NCI)
Phase 1
1998-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients
who have advanced solid tumors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
